In vitro susceptibility testing demonstrates broad antifungal resistance in clinical Lomentospora prolificans isolates, highlighting potential utility for miltefosine.
Lomentospora prolificans is an opportunistic fungal pathogen with low susceptibility to current antifungal drugs. Here, we tested the in vitro susceptibility of 8 drugs against 42 clinical L. prolificans isolates. All isolates showed high MICs to voriconazole (MIC 90 >16 μg/ml), itraconazole (MIC 90 >16 μg/ml), posaconazole (MIC 90 >16 μg/ml), isavuconazole (MIC 90 >16 μg/ml), amphotericin B (MIC 90 >16 μg/ml), and terbinafine (MIC 90 >64 μg/ml) and high minimum effective concentrations (MECs) to micafungin (MEC 90 >8 μg/ml), with the exception of miltefosine showing an MIC 90 value of 4 μg/ml.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: